Back to search

Article

Early ctDNA kinetics as a dynamic biomarker of cancer treatment response

2024-07-03

Abstract excerpt

Circulating tumor DNA assays are promising tools for the prediction of cancer treatment response. Here, we build a framework for the design of ctDNA biomarkers of therapy response that incorporate variations in ctDNA dynamics driven by specific treatment mechanisms. We develop mathematical models of ctDNA kinetics driven by tumor response to several therapy classes, and utilize them to simulate randomized virtual...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
023e3a1b-69bc-5dd4-863c-bc5e46fa761d
DOI
10.1101/2024.07.01.601508
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseDOI 10.1101/2024.07.01.601508
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challengesSemantic proximity
Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology.Semantic proximity
Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response.Semantic proximity
Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON studySemantic proximity
Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer StudySemantic proximity
SHERLOC: An interpretable deep learning model for longitudinal circulating tumor DNA data in survival analysisSemantic proximity
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.Semantic proximity
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.Semantic proximity
Natural history model predicts benefits associated with screening for lung cancer by detecting circulating tumor DNASemantic proximity
A Novel Cell-Free DNA Fragmentomics Assay and Its Application for Monitoring Disease Progression in Real-Time for Stage IV Cancer PatientsSemantic proximity
Integrating ctDNA Dynamics and Sequential Organoid Drug Screening Enhances Breast Cancer Treatment Efficacy.Semantic proximity
Improving prediction of survival and progression in metastatic non-small cell lung cancer following immunotherapy through machine learning of circulating tumor DNA dynamicsSemantic proximity
Select a neighboring publication to make it the new centre.